While BRAF mutation is a diagnostic and prognostic biomarker, it may be a predictive biomarker concerning tyrosine kinase inhibitors (TKIs), such as vemurafenib and dabrafenib, for lung cancer and melanoma patients [4]. This evidence concerns the gene BRAF and melanoma.